ArticleOncotarget2018

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.

Veronika Reidel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.